egfrcancer.org
Deep Dive: Afatinib+Cetuximab for T790M Neg Patients With Acquired Resistance
*March 2019* This is an overview (written by Donald Ox) of the current EGFR TKIs and acquired resistance leading to the effectiveness of the afatinib + cetuximab combo treatment especially useful for T790M negative patients who developed acquired resistance to Iressa/Tarceva/Afatinib, as many in our group queried about their options other than chemo.Somatic mutations in